Drug Profile
Research programme: RNA therapeutics - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine
Alternative Names: Human alpha-1 antitrypsin messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; Human erythropoietin messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; Human factor IX messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; Human tumor protein p53 messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; LUNAR-101; LUNAR-102; LUNAR-FIX; LUNAR-hepcidin messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; LUNAR-HPN; LUNAR-ornithine transcarbamylase messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; LUNAR-thrombopoietin messenger RNA - Arcturus Therapeutics/Johnson & Johnson Innovative Medicine; LUNAR-TPOLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Class Antianaemics; Antifibrotics; Antineoplastics; MicroRNAs; RNA; Small interfering RNA
- Mechanism of Action RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency; Amyloid polyneuropathy; Amyloidosis; Anaemia; Cancer; Haemophilia B; Iron overload; Ornithine carbamoyltransferase deficiency disease; Thrombocytopenia
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Ornithine-carbamoyltransferase-deficiency-disease in USA (Parenteral)
- 28 Nov 2018 No recent reports of development identified for research development in Iron-overload in USA (Parenteral)